Community treatment of severe, refractory obsessive-compulsive disorder.
Despite the existence of effective psychological and pharmacological interventions for obsessive-compulsive disorder (OCD), there are a large proportion of individuals for whom intervention is not effective. The study reports on the results of a community treatment service for individuals with treatment-refractory OCD who have not benefitted from previous cognitive behavioural or pharmacological treatment by community mental health services. A total of 205 individuals accepted for treatment by a specialist community OCD treatment service in London were provided with a combination of behavioural, cognitive, and pharmacological treatment within a specialist OCD service, with 158 completing treatment. Treatment was associated with significant reduction in clinician-rated and self-reported OCD symptoms after 12 weeks, with further reductions in OCD symptoms over a subsequent 12-week period. A significant reduction in symptoms of depression was also observed after 12 and 24 weeks. Approximately 40% of individuals treated experienced clinically significant improvement in their symptoms, with approximately 10% deemed to have recovered by the end of treatment. Our results add to previous research into refractory OCD, and provide support for the existence of specialist community treatment services which may provide assistance to individuals who have not responded to previous treatment.
School of Psychology, Griffith University, Gold Coast, Parklands Drive, Southport Q 4215, Australia. m.boschen@griffith.edu.au
Mark J
MJ
Boschen
Lynne M
LM
Drummond
D000328:Adult; D014151:Anti-Anxiety Agents / Q000627:therapeutic use*; D001521:Behavior Therapy / Q000379:methods*; D002908:Chronic Disease; D015331:Cohort Studies; D003131:Combined Modality Therapy; D003156:Community Mental Health Services; D003863:Depression / Q000628:therapy; D005260:Female; D006801:Humans; D008131:London; D008297:Male; D009771:Obsessive-Compulsive Disorder / Q000628:therapy*; D012017:Referral and Consultation; D016896:Treatment Outcome
D014151:Anti-Anxiety Agents